[Asia Economy Reporter Chunhee Lee] CrystalGenomics announced on the 1st that the pancreatic cancer drug candidate substance ‘Ivaltinostat’ has been granted a patent in Brazil. The patent title is ‘Pharmaceutically acceptable salts of alkylcarbamoyl naphthalenyl oxy octenoyl hydroxamic acid or its derivatives and their manufacturing methods.’
This salt patent improves moisture stability while maintaining characteristics such as efficacy and effective dosage of Ivaltinostat, enabling commercial production. Through this, the manufacturing of Ivaltinostat raw materials is facilitated, improving solubility, enhancing the physicochemical stability of the raw material itself, and allowing powder formulation, which can significantly improve profitability upon commercialization. It was also added that, in addition to the existing injectable form, the possibility of developing various formulations including oral formulations that can improve patient compliance is open.
Ivaltinostat strongly inhibits only Class I and Class IIb histone deacetylases (HDAC) and does not inhibit other proteins, so unlike existing pancreatic cancer treatments, it is evaluated that serious side effects in normal cells are not expected.
This patent is valid until April 18, 2038. During this period, it will fundamentally prevent other companies from manufacturing the same salt.
A CrystalGenomics official said, “We will continue to expand patent rights related to Ivaltinostat by country to increase the possibility of licensing technology exports according to clinical development in the United States.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
